US to experiment three drugs to treat inflammation caused by Covid-19

US to experiment three drugs to treat inflammation caused by Covid-19. The United States is starting another study that will test three drugs to slow an overactive response by the immune system that can cause severe disease or even death in people who have contracted Covid-19.

For the study, the US National Institutes of Health will enroll 2,100 hospitalized adults with moderate to severe Covid-19 in the United States and Latin America, the Associated Press reported.

All participants in the study will get the antiviral drug Remdesivir plus one of the three “immune-modulating drugs” or a placebo. The drugs are Bristol Myers Squibb’s Orencia, Johnson and Johnson’s Remicade, which are sold now for rheumatoid arthritis, and an experimental drug from AbbVie called Cenicriviroc.

According to the report, these drugs work in different approaches to inhibit ‘cytokine storm’ for example an overproduction of synthetics that the body produces to fight infections but can also damage lungs, kidneys, heart and other organs.

“These are all different methods of slowing down an overactive immune system,” NIH director Dr Francis Collins, was quoted as saying.

The new study is the fifth and final one of every a progression of experiments that are designed by a private-public partnership and includes many drug companies, non-profit groups and various US government departments.

Other therapies that are being tested include antibody drugs, anti-inflammatory medicines and plasma from Covid-19 survivors.

Earlier, clinical trial by the World Health Organization (WHO) has discovered that remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or odds of endurance.

A ‘Solidarity’ trial by the WHO evaluated the effects of four potential drug regimens – remdesivir, hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon – in 11,266 adult patients across more than 30 countries.

The study found the regimens appeared to have little or no effect on 28-day mortality or the length of the in-hospital course among patients hospitalized with Covid-19, the WHO was quoted as saying by Reuters. The results of the trial are yet to be reviewed.

Read More Article…

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

World News Today will use the information you provide on this form to be in touch with you and to provide updates and marketing.